Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

There is a pitiful absence of good and effective drugs for oral mucositis.

Here is a report from another place.
"The management of oral mucositis is a challenge, due to its complex biological nature.
Several interventions for the prevention of oral mucositis, such as oral hygiene protocols, amifostine, benzidamine, calcium phosphate, cryotherapy and iseganan, among others, were found to yield only limited benefits.
Very few interventions of confirmed efficacy are available for the management of oral mucositis due to chemotherapy."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808317/

Here is another.
"Mucositis is a common and feared complication of anticancer therapy that can affect up to 90% of certain populations of patients with cancer. Even seemingly uncomplicated mucositis, which is often self-limited, can result in intense patient discomfort and decline in quality of life. Severe mucositis can be complicated by uncontrolled pain, superinfection or systemic infection, bleeding, and dehydration, and severe mucositis can lead to interruptions or de-escalation in anticancer treatment, resulting in worse oncologic outcomes."
https://ascopubs.org/doi/full/10.1200/JOP.19.00652

Here is one more.
"Despite its clinically devastating consequences, there is little to offer patients in the way of effective treatment to prevent or mitigate mucositis, and oral and gastrointestinal mucositis continues to present a significant challenge to patients undergoing cancer therapy.

An alternative approach was taken by Innovation Pharmaceuticals, which tested their defensin mimetic, Brilacidin, in a small phase 2 trial (ClinicalTrials.gov identifier NCT02324335). Data from the study completed in 2018 showed that Brilacidin administered as an oral rinse favorably affected the incidence of SOM by 65% compared with placebo (Brilacidin, 25.0%; placebo, 71.4%; P = .0480).115, 116 Unlike avasopasem manganese, for which efficacy was independent of cisplatin regimen, Brilacidin was more effective in patients being treated when cisplatin was administered triweekly at a high dose (vs weekly at a low dose)."
https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21704?af=R

Happy here to own Ipix and Brilacidin.